Regulus Therapeutics
RGLS
$2.26
Share price
2.73%
Change (1 day)
66.18%
Change (1 year)
Categories
Revenue for Regulus Therapeutics (RGLS)
Revenue in 2023 (TTM): N/A
In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Regulus Therapeutics from 2012 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | N/A | |
| 2022 | N/A | |
| 2021 | N/A | -100% |
| 2020 | $10 M | 46.46% |
| 2019 | $6.83 M | 9388.89% |
| 2018 | $0.07 M | 0% |
| 2017 | $0.07 M | -93.97% |
| 2016 | $1.19 M | -94.25% |
| 2015 | $20.75 M | 170.69% |
| 2014 | $7.66 M | -60.81% |
| 2013 | $19.56 M | 54.09% |
| 2012 | $12.7 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $50.35 B | N/A | 🇫🇷 France |
 Biogen BIIB | $9.83 B | N/A | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $45.00 B | N/A | 🇺🇸 USA |
 AstraZeneca AZN | $45.81 B | N/A | 🇬🇧 UK |
 GlaxoSmithKline GSK | $37.84 B | N/A | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | $0.17 B | N/A | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | $0.19 B | N/A | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $1.82 B | N/A | 🇺🇸 USA |